Search: onr:"swepub:oai:gup.ub.gu.se/282536" > Use of fast-acting ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03910naa a2200421 4500 | |
001 | oai:gup.ub.gu.se/282536 | |
003 | SwePub | |
008 | 240528s2019 | |||||||||||000 ||eng| | |
024 | 7 | a https://gup.ub.gu.se/publication/2825362 URI |
024 | 7 | a https://doi.org/10.1111/dom.137982 DOI |
040 | a (SwePub)gu | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Evans, M.4 aut |
245 | 1 0 | a Use of fast-acting insulin aspart in insulin pump therapy in clinical practice |
264 | c 2019-06-19 | |
264 | 1 | b Wiley,c 2019 |
520 | a Fast-acting insulin aspart (faster aspart) is a novel formulation of insulin aspart (IAsp) containing the additional excipients niacinamide and L-arginine. The improved pharmacological profile and greater early glucose-lowering action of faster aspart compared with IAsp suggests that faster aspart may be advantageous for people with diabetes using continuous subcutaneous insulin infusion (CSII). The recent onset 5 trial was the first to evaluate the efficacy and safety of an ultra-fast-acting insulin in CSII therapy in a large number of participants with type 1 diabetes (T1D). Non-inferiority of faster aspart to IAsp in terms of change from baseline in HbA1c was confirmed, with an estimated treatment difference (ETD) of 0.09% (95% CI, 0.01; 0.17; P < 0.001 for non-inferiority [0.4% margin]). Faster aspart was superior to IAsp in terms of change from baseline in 1-hour post-prandial glucose (PPG) increment after a meal test (ETD [95% CI], −0.91 mmol/L [−1.43; −0.39]; P = 0.001), with statistically significant improvements also at 30 minutes and 2 hours. The overall rate of severe or blood glucose-confirmed hypoglycaemia was not statistically significantly different between treatments, with an estimated rate ratio of 1.00 (95% CI, 0.85; 1.16). A numerical imbalance in severe hypoglycaemic episodes between faster aspart and IAsp was seen in the treatment (21 vs 7) and the 4-week run-in periods (4 vs 0). Experience from clinical practice indicates that all pump settings should be reviewed when initiating faster aspart with CSII, and that the use of continuous glucose monitoring or flash glucose monitoring, along with a good understanding of meal content and bolus type, may also facilitate optimal use. This review summarizes the available clinical evidence for faster aspart administered via CSII and highlights practical considerations based on clinical experience that may help healthcare providers and individuals with T1D successfully initiate and adjust faster aspart with CSII. © 2019 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Endokrinologi och diabetes0 (SwePub)302052 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Endocrinology and Diabetes0 (SwePub)302052 hsv//eng |
653 | a CSII | |
653 | a insulin pump therapy | |
700 | 1 | a Ceriello, A.4 aut |
700 | 1 | a Danne, T.4 aut |
700 | 1 | a De Block, C.4 aut |
700 | 1 | a DeVries, J. H.4 aut |
700 | 1 | a Lind, Marcus,d 1976u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine4 aut0 (Swepub:gu)xostem |
700 | 1 | a Mathieu, C.4 aut |
700 | 1 | a Nørgaard, K.4 aut |
700 | 1 | a Renard, E.4 aut |
700 | 1 | a Wilmot, E. G.4 aut |
710 | 2 | a Göteborgs universitetb Institutionen för medicin, avdelningen för molekylär och klinisk medicin4 org |
773 | 0 | t Diabetes, Obesity and Metabolismd : Wileyg 21:9, s. 2039-2047q 21:9<2039-2047x 1462-8902x 1463-1326 |
856 | 4 | u https://doi.org/10.1111/dom.13798 |
856 | 4 8 | u https://gup.ub.gu.se/publication/282536 |
856 | 4 8 | u https://doi.org/10.1111/dom.13798 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.